RESMED INC 8-K

What Happened
ResMed Inc. announced on April 30, 2026 that Brett Sandercock will retire as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer and will remain in those CFO roles through May 4, 2026. Immediately following, Sandercock will become Special Advisor to CEO Mick Farrell through December 31, 2026 and will continue in a consulting Special Advisor role from January 1–December 31, 2027. The company also appointed Aaron Bloomer (age 40) as CFO, Principal Financial Officer and Principal Accounting Officer, effective May 4, 2026. ResMed issued a press release announcing these changes the same day.

Key Details

• Brett Sandercock will continue receiving his current salary, benefits and equity vesting, and is eligible for a six‑month pro‑rata short‑term incentive payment for fiscal 2027; his retirement was not due to any disagreement with the company.
• Aaron Bloomer’s compensation package on hire: $725,000 annual base salary; $150,000 sign‑on bonus (repayable if he voluntarily leaves within 24 months); short‑term cash incentive target of 80% of base (payable pro‑rata for FY2026).
• Bloomer will receive a $3,300,000 long‑term performance equity sign‑on grant (split 50/50 between restricted stock units and performance stock units; performance PSUs split between absolute and relative TSR vs. the S&P 500), plus relocation assistance.
• Bloomer is also eligible for an additional $3,300,000 equity grant in November 2026 (subject to committee approval) and will participate in the company’s executive severance and change‑in‑control arrangements.

Why It Matters
A CFO transition affects financial leadership and investor oversight. ResMed named an experienced external finance executive (Aaron Bloomer, formerly CFO at Exact Sciences and with senior roles at Baxter and 3M) and preserved continuity by keeping Sandercock on as an advisor/consultant through 2027 with continued pay and equity vesting. Investors should note the material compensation and equity awards tied to Bloomer’s hire (base pay, sign‑on bonus, and multi‑million dollar equity grants) which reflect the company’s approach to retaining senior finance talent and aligning pay with long‑term shareholder performance.